Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex

Documenti analoghi

• Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand
  di: Sara Mustafa, et al.
  Pubblicazione: (2025)
• Gender differences in the prescription of SGLT2 inhibitors in chronic kidney disease: A real‐world database study
  di: Tatsuhiko Azegami, et al.
  Pubblicazione: (2025)
• Predictors of diabetic ketoacidosis in patients with insulin‐deficient diabetes phenotype initiating SGLT2 inhibitors
  di: Anat Tsur, et al.
  Pubblicazione: (2025)
• Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
  di: Hannah Wallace, et al.
  Pubblicazione: (2025)
• Adherence to GLP ‐1 receptor agonists and SGLT2 inhibitors by out‐of‐pocket spending among Medicare beneficiaries with diabetes
  di: Nicklas S. Klepser, et al.
  Pubblicazione: (2025)